Related Experiment Video
Updated: May 23, 2026
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
[Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice]
Yun-Bei Xiao1, Jing Xie, Gou-Xi Zhang
1Department of Urology, People's Hospital of Peking University, Beijing 100044, China.
Objective:
To investigate the inhibitory effect of CKLF-like MARVEL transmembrane domain containing 5 (CMTM5) on xenografted human prostatic cancer in nude mice and its action mechanism.
Methods:
We established a model of xenografted prostatic cancer by inoculating PC-3 cells subcutaneously into nude mice, and 3 weeks later injected CMTM5 adenovirus locally into the tumor followed by daily observation of the tumor volume and body weight of the experimental animals. All the rats were killed 2 weeks after CMTM5 injection and the tumor tissue harvested for detection of the inhibitory effect of CMTM5 on the expressions of VEGF and NF-kappaB proteins by immunohistochemistry.
Results:
The tumor volume was significantly smaller and body weight of the CMTM5-treated mice were (573.39 +/- 175.24) mm3 and (0.55 +/- 0.11) g, respectively, significantly decreased as compared with those of the controls ([1482.50 +/- 327.86] mm3 and [1.31 +/- 0.29] g) (P = 0.03 and P = 0.027). Immunohistochemistry showed that the expressions of VEGF and NF-kappaB were obviously down-regulated in the CMTM5 group in comparison with the control group.
Conclusion:
CMTM5 suppresses the growth of prostate cancer by down-regulating the expressions of VEGF and NF-kappaB.
Insights
CMTM5 (CKLF-like MARVEL transmembrane domain containing 5) significantly inhibited prostate cancer growth in mice by reducing VEGF and NF-kappaB protein expression. This finding offers a potential therapeutic strategy for prostate cancer. Keywords: CMTM5, prostate cancer, VEGF, NF-kappaB.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Context:
- Prostate cancer is a significant global health concern.
- Understanding the molecular mechanisms underlying prostate cancer growth is crucial for developing effective therapies.
- The role of specific genes and proteins in tumor progression requires further investigation.
Purpose:
- To evaluate the inhibitory effect of CMTM5 on xenografted human prostate cancer in nude mice.
- To elucidate the mechanism by which CMTM5 affects tumor growth, specifically its impact on VEGF and NF-kappaB.
- To assess the potential of CMTM5 as a therapeutic agent for prostate cancer.
Summary:
- A xenograft model of human prostate cancer (PC-3 cells) was established in nude mice.
- CMTM5 adenovirus was administered intratumorally, leading to a significant reduction in tumor volume and body weight compared to controls.
- Immunohistochemical analysis revealed downregulation of VEGF and NF-kappaB protein expression in CMTM5-treated tumors.
Impact:
- CMTM5 demonstrates a potent tumor-suppressive effect on prostate cancer xenografts.
- The downregulation of VEGF and NF-kappaB by CMTM5 suggests a novel therapeutic pathway.
- These findings support CMTM5 as a potential candidate for future prostate cancer treatment strategies.
